Patents by Inventor Ruchi Jain

Ruchi Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12246030
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: March 11, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
  • Patent number: 12241030
    Abstract: The present invention relates to an additized blended fuel composition comprising of 97 to 50 weight % of liquified petroleum gas (LPG); 3 to 50 weight % of dimethyl ether (DME); and a nanocatalyst. More particularly, the present invention relates to an improvement in the combustion efficiency of the DME blended LPG fuel by using catalytic amount of the nano-catalyst, when introduced in ppm level enhances the combustion properties, thereby increasing the flame temperature and reducing the consumption of fuel gas mixture.
    Type: Grant
    Filed: October 17, 2023
    Date of Patent: March 4, 2025
    Assignee: INDIAN OIL CORPORATION LIMITED
    Inventors: Koushik Bhowmik, Ruchi Jain, Jyotiranjan Ota, Samik Kumar Hait, Chandrasekaran Kannan, Sankara Sri Venkata Ramakumar
  • Patent number: 12241063
    Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: March 4, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Melissa J. Moore, Caroline Köhrer, Ruchi Jain, Vladimir Presnyak
  • Publication number: 20240384277
    Abstract: The disclosure features compositions or systems and uses thereof, comprising a first polynucleotide encoding a target molecule, optionally a second polynucleotide encoding an effector, repressor, or endonuclease molecule; optionally a recognition or cleavage site in the first or second polynucleotide, and optionally a repressor/effector binding site in the first polynucleotide. The compositions or systems of the present disclosure can increase the level and/or activity of the target molecule in desired cells and/or microenvironments while suppressing the level and/or activity of the target molecule in off-target cells and/or microenvironments.
    Type: Application
    Filed: June 14, 2022
    Publication date: November 21, 2024
    Inventors: Ruchi Jain, Brian Robert Fritz, Mihir Metkar
  • Publication number: 20240269248
    Abstract: This disclosure relates to mRNA therapy for the treatment of methylmalonic acidemia (MMA). mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase (MUT). mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.
    Type: Application
    Filed: May 19, 2022
    Publication date: August 15, 2024
    Inventors: Husain Attarwala, Kimberly Ann Coughlan, Ruchi Jain, Matthew Lumley, Vladimir Presnyak
  • Publication number: 20240226025
    Abstract: This disclosure relates to messenger RNA (mRNA) therapy for the treatment of methylmalonic acidemia. mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase. mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 11, 2024
    Inventors: Kerry Benenato, Mark Cornebise, Edward Hennessy, Ruchi Jain, Vladimir Presnyak
  • Publication number: 20240189449
    Abstract: This disclosure relates to mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC). mRNA therapies of the disclosure increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the disclosure further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
    Type: Application
    Filed: March 24, 2022
    Publication date: June 13, 2024
    Inventors: Kerry Benenato, Alicia Anne Bicknell, Mark Cornebise, Athanasios Dousis, Andrew Jacob Giessel, Edward Hennessy, Ruchi Jain, Caroline Köhrer, Stuart Spencer Licht, Kanchana Ravichandran, David Reid
  • Patent number: 11968981
    Abstract: The present invention relates to an anti-viral nanoformulation suitable for diverse surface application in form of hydrogel based nanoemulsion, or an aerosol spray. The present invention discloses incorporation of nanomaterials such as functionalized carbon quantum dots (F-CQDs), copper nanoparticles (CuNPs) or silver nanoparticles (AgNPs) into the hydrogel (HG) scaffold to act as chemical barrier and anti-viral agent against SARS-CoV-2 or Escherichia coli: phage MS2. The nanoformulation is coated on personal protective equipment's (PPE) and different surfaces such as glass, steel and plastic to control viral infection including corona virus infection.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: April 30, 2024
    Assignee: INDIAN OIL CORPORATION LIMITED
    Inventors: Mani Gajendiran, Ruchi Jain, Arjyabaran Sinha, Koushik Bhowmik, Om Parkash, Mukesh Kumar Vyas, Jyotiranjan Ota, Samik Kumar Hait, Vivekanand Kagdiyal, Deepak Saxena, Sankara Sri Venkata Ramakumar
  • Publication number: 20240124793
    Abstract: The present invention relates to an additized blended fuel composition comprising of 97 to 50 weight % of liquified petroleum gas (LPG); 3 to 50 weight % of dimethyl ether (DME); and a nanocatalyst. More particularly, the present invention relates to an improvement in the combustion efficiency of the DME blended LPG fuel by using catalytic amount of the nano-catalyst, when introduced in ppm level enhances the combustion properties, thereby increasing the flame temperature and reducing the consumption of fuel gas mixture.
    Type: Application
    Filed: October 17, 2023
    Publication date: April 18, 2024
    Applicant: INDIAN OIL CORPORATION LIMITED
    Inventors: Koushik BHOWMIK, Ruchi JAIN, Jyotiranjan OTA, Samik Kumar HAIT, Chandrasekaran KANNAN, Sankara Sri Venkata RAMAKUMAR
  • Publication number: 20230338410
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 26, 2023
    Inventors: Stephen HOGE, Tirtha CHAKRABORTY, Gilles BESIN, Ruchi JAIN
  • Publication number: 20230257738
    Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
    Type: Application
    Filed: September 20, 2022
    Publication date: August 17, 2023
    Inventors: Melissa J. MOORE, Caroline KÖHRER, Ruchi JAIN, Vladimir PRESNYAK
  • Publication number: 20230242908
    Abstract: The disclosure features a polynucleotide encoding a polypeptide, which polynucleotide comprises: a 5?UTR described herein; a coding region comprising a payload and a stop element described herein; and a 3?UTR described herein, and LNP compositions comprising the same. The polynucleotides and/or LNP compositions of the present disclosure can: increase the level and/or activity of the payload by increasing the half-life and/or duration of expression of the polynucleotide encoding the payload or of the payload polypeptide. Also disclosed herein are methods of treating a disease or disorder in a subject using the LNP compositions of the present disclosure.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 3, 2023
    Inventors: David Reid, Ruchi Jain, Alicia Bicknell, Caroline Kohrer
  • Publication number: 20230173104
    Abstract: The disclosure features LNP compositions and systems comprising a therapeutic payload or prophylactic payload, a binding element, a tether molecule and/or an effector molecule and uses thereof. The LNP compositions or systems of the present disclosure comprise: (a) a first polynucleotide (e.g., mRNA) comprising: (1) a sequence encoding a therapeutic payload or prophylactic payload, and (2) a binding element; and (b) a second polynucleotide (e.g., mRNA) comprising a sequence encoding: (1) an effector molecule, and/or (2) a polypeptide that recognizes the binding element (a tether molecule). Such compositions or systems can: increase the level and/or activity of the therapeutic payload or prophylactic payload, e.g., increase the level, stability and/or activity of the mRNA encoding the therapeutic payload or prophylactic payload. Also disclosed herein are methods of treating a disorder, or for modulating an immune response in a subject using the disclosed LNP compositions or systems.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 8, 2023
    Inventors: Ruchi Jain, Alicia Anne Bicknell
  • Publication number: 20230086537
    Abstract: The disclosure features mRNAs engineered with one or more microRNA binding sites targeted by a microRNA(s) that are differentially expressed in a target immune cell relative to a plurality of non-target immune cells. The disclosure also features methods of using the same, for example, for selectively degrading the mRNA in the target immune cell relative to the plurality of non-target immune cells.
    Type: Application
    Filed: May 7, 2020
    Publication date: March 23, 2023
    Inventors: Ruchi JAIN, Gilles BESIN, Elizaveta ANDRIANOVA
  • Patent number: 11590157
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: February 28, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
  • Patent number: 11590177
    Abstract: The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: February 28, 2023
    Assignee: The Johns Hopkins University
    Inventors: William R. Bishai, Ruchi Jain Dey, Bappaditya Dey, Laurene Cheung
  • Publication number: 20220387628
    Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide desirable regulation of mRNA localization, stability, and/or translation to yield increased mRNA expression and activity of an encoded polypeptide.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 8, 2022
    Inventors: Ruchi JAIN, David REID, Vladimir PRESNYAK, Alicia BICKNELL, Caroline KÖHRER
  • Patent number: 11485972
    Abstract: The present disclosure provides messenger RNAs (mRNAs) having chemical and/or structural modifications, including RNA elements and/or modified nucleotides, which provide a desired translational regulatory activity to the mRNA.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Melissa J. Moore, Caroline Köhrer, Ruchi Jain, Vladimir Presnyak
  • Publication number: 20220110328
    Abstract: The present invention relates to an anti-viral nanoformulation suitable for diverse surface application in form of hydrogel based nanoemulsion, or an aerosol spray. The present invention discloses incorporation of nanomaterials such as functionalized carbon quantum dots (F-CQDs), copper nanoparticles (CuNPs) or silver nanoparticles (AgNPs) into the hydrogel (HG) scaffold to act as chemical barrier and anti-viral agent against SARS-CoV-2 or Escherichia coli: phage MS2. The nanoformulation is coated on personal protective equipment's (PPE) and different surfaces such as glass, steel and plastic to control viral infection including corona virus infection.
    Type: Application
    Filed: March 24, 2021
    Publication date: April 14, 2022
    Inventors: Mani GAJENDIRAN, Ruchi JAIN, Arjyabaran SINHA, Koushik BHOWMIK, Om PARKASH, Mukesh Kumar VYAS, Jyotiranjan OTA, Samik Kumar HAIT, Vivekanand KAGDIYAL, Deepak SAXENA, Sankara Sri Venkata RAMAKUMAR
  • Publication number: 20210260097
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Application
    Filed: September 29, 2020
    Publication date: August 26, 2021
    Inventors: Stephen HOGE, Tirtha CHAKRABORTY, Gilles BESIN, Ruchi JAIN